Equibles does not estimate personal net worth.
Get an email with a short summary when Travere Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get TVTX alertsChristopher Cline is recorded as CFO at Travere Therapeutics, Inc. (TVTX). The newest filing on record that lists Christopher Cline as CFO at Travere Therapeutics, Inc. (TVTX) is dated April 6, 2026. The proxy statement of Travere Therapeutics, Inc. reports total compensation of $2,250,914 for Christopher Cline in fiscal 2025, including a base salary of $522,917. Disclosed compensation is on record for 4 fiscal years. Christopher Cline has spoken on 4 earnings calls across 1 company, most recently for Travere Therapeutics, Inc. on May 4, 2026. Travere Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Travere Therapeutics, Inc. includes Bradley Campbell (CEO and Board Member), Bradley L. Campbell (CEO and Board Member), Elizabeth E. Reed (General Counsel) and 7 others.
“As you've heard from the team, we delivered another strong quarter of execution across the business. And recently, we achieved an important milestone with Filspari's approval on FSGS that further strengthens our outlook for continued growth.”
“Prakhar, thanks for the question on gross-to-net. And as you would expect, we did see some relief this quarter relative to last quarter once we got through the typical beginning of the year dynamics.”
“Our first quarter performance was highlighted by continued strong execution across the organization as well as the strengthening of our financial position. For the first quarter of 2023, net product sales were $50.3 million compared to $46.4 million from the same period in 2022.”
“With the continued execution of our commercial organization and the focus on our key priorities throughout the business, we ended 2022 in a strong financial position.”
Start not stated–present
Last confirmed April 6, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Travere Therapeutics, Inc. (TVTX) | Chief Financial Officer | $522,917 | $2,250,914 |
| 2024 | Travere Therapeutics, Inc. (TVTX) | Chief Financial Officer | $497,500 | $1,501,520 |
| 2023 | Travere Therapeutics, Inc. (TVTX) | Chief Financial Officer | $466,667 | $1,971,490 |
| 2022 | Travere Therapeutics, Inc. (TVTX) | Chief Financial Officer | $397,204 | $2,325,646 |
